Investors Scrutinize Capricor Therapeutics After FDA Data Concerns

The volatility stems from an internal FDA review of deramiocel, a treatment for a heart condition linked to Duchenne muscular dystrophy. Staff reviewers questioned the therapy's overall effectiveness and its risk-benefit profile ahead of an external advisory committee meeting scheduled for Wednesday. This regulatory scrutiny wiped out more than half of the company’s market value in a single trading session.

Rosen Law is now evaluating potential securities claims on behalf of investors who suffered losses during the price swing. The firm, which specializes in shareholder litigation, is soliciting inquiries from those who purchased stock, citing allegations that Capricor may have released inaccurate business information. Interested parties are directed to contact attorney Phillip Kim to discuss the prospective class action, which operates on a contingency fee basis.